| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1367 | 2021 |
| Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence RK Vaddepally, P Kharel, R Pandey, R Garje, AB Chandra Cancers 12 (3), 738, 2020 | 1046 | 2020 |
| Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors P Vikas, N Borcherding, A Chennamadhavuni, R Garje Frontiers in oncology 10, 570, 2020 | 144 | 2020 |
| Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA P Barata, N Agarwal, R Nussenzveig, B Gerendash, E Jaeger, W Hatton, ... Journal for immunotherapy of cancer 8 (2), 2020 | 85 | 2020 |
| Comprehensive review of chromophobe renal cell carcinoma R Garje, D Elhag, HA Yasin, L Acharya, D Vaena, L Dahmoush Critical reviews in oncology/hematology 160, 103287, 2021 | 62 | 2021 |
| Obesity diminishes response to PD-1-based immunotherapies in renal cancer SK Boi, RM Orlandella, JT Gibson, WJ Turbitt, G Wald, L Thomas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 59 | 2020 |
| [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. P Kuo, J Hesterman, K Rahbar, AT Kendi, XX Wei, B Fang, N Adra, ... Journal of Clinical Oncology 40 (16_suppl), 5002-5002, 2022 | 57 | 2022 |
| Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer R Garje, J An, M Obeidat, K Kumar, HA Yasin, Y Zakharia The oncologist 25 (11), e1711-e1719, 2020 | 40 | 2020 |
| The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma R Garje, J An, A Greco, RK Vaddepally, Y Zakharia Cancers 12 (1), 143, 2020 | 40 | 2020 |
| Understanding the redox biology of selenium in the search of targeted cancer therapies JM Stolwijk, R Garje, JC Sieren, GR Buettner, Y Zakharia Antioxidants 9 (5), 420, 2020 | 36 | 2020 |
| Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience A Kaur, T Doberstein, RR Amberker, R Garje, EH Field, N Singh Medicine 98 (41), e17348, 2019 | 35 | 2019 |
| Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer R Garje, A Chennamadhavuni, SL Mott, IM Chambers, P Gellhaus, ... Clinical genitourinary cancer 18 (2), e157-e166, 2020 | 31 | 2020 |
| Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline P Vikas, H Messersmith, C Compton, L Sholl, RR Broaddus, A Davis, ... Journal of clinical oncology 41 (10), 1943-1948, 2023 | 29 | 2023 |
| Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic … B Tran, L Horvath, M Rettig, K Fizazi, MP Lolkema, TB Dorff, R Greil, ... Journal of Clinical Oncology 38 (15_suppl), TPS5590-TPS5590, 2020 | 29 | 2020 |
| Current landscape and the potential role of hypoxia-inducible factors and selenium in clear cell renal cell carcinoma treatment R Garje, JJ An, K Sanchez, A Greco, J Stolwijk, E Devor, Y Rustum, ... International journal of molecular sciences 19 (12), 3834, 2018 | 29 | 2018 |
| Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge R Vaddepally, R Doddamani, S Sodavarapu, NR Madam, R Katkar, ... Biomedicines 10 (4), 790, 2022 | 25 | 2022 |
| PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer VS Koshkin, VG Patel, A Ali, MA Bilen, D Ravindranathan, JJ Park, ... Prostate cancer and prostatic diseases 25 (3), 388-396, 2022 | 22 | 2022 |
| Dabigatran-related leukocytoclastic vasculitis J An, R Garje, KA Wanat, JP Leone Case Reports 2017, bcr2016217423, 2017 | 17 | 2017 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria RL Shrode, JE Knobbe, N Cady, M Yadav, J Hoang, C Cherwin, M Curry, ... Scientific reports 13 (1), 526, 2023 | 16 | 2023 |
| PARP inhibitors in prostate and urothelial cancers R Garje, RK Vaddepally, Y Zakharia Frontiers in oncology 10, 114, 2020 | 16 | 2020 |
Raju K VaddepallyYuma Regional Medical CenterVerified email at yumaregional.org
